Determination of CMV-specific T-cell frequencies after allogeneic or haploidentical hematopoietic stem cell transplantatio
- Conditions
- Patients after allogeneic or haploidentical blood stem cell transplantation
- Registration Number
- DRKS00031287
- Lead Sponsor
- niversitätsklinikum Düsseldorf
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
CMV IgG-positive donor or recipient
Condition after allogeneic or haploidentical blood stem cell transplantation
Signed informed consent form
Exclusion Criteria
No capacity to consent
Refusal to participate
Donor or recipient CMV IgG-negative
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of patients at risk for CMV reactivation after allogeneic or haploidentical hematopoietic stem cell transplantation despite prophylaxis with letermovir. For this purpose, a so-called ELISPOT examination from peripheral blood will be performed at different time points after transplantation (day +100, +200, as well as at the first CMV detection by PCR and 1 and 3 months after CMV reactivation and - if necessary - in the further course). This examination allows to estimate the frequency of CMV-specific T cells in the patient's blood.
- Secondary Outcome Measures
Name Time Method To determine the duration to reconstitution of CMV-specific T cells after transplantation with CMV+ and CMV- donors. Determination of a threshold for sufficient T cell activity to prevent CMV reactivation.